Clinical Trial

Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy

Study acronym: CIRCADIAN
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 19, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-11.
Trial Details
NCT Number NCT06880029
Lead Sponsor Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Conditions Triple Negative Breast Cancer (TNBC)
Enrollment 20 participants
Start Date 2024-09-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2025-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-19